Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Eric Freeman who wrote (7060)	3/26/1998 9:24:00 AM
From: Webhead	Read Replies (1) \| Respond to of 8116

I am much less sanguine about this piece of news. I, once again, feel betrayed by Cytogen management; the names may change but the final result is the same => loyal shareholders get screwed! I hope that I'm wrong about what I expect today (tank city) but even if price holds up I'm still going to be angry over several points: 1) McKearn AND Bagly both promised a first quarter ALT submission. In fact McKearn was supposed to supply his "expertise" with the FDA to make sure that the submission was the best possible. 2) The ALT trial results for Hepatitus C were never released though one the the "letters to shareholders" mentioned the upcoming presentation. One can only wonder if ALT was at all effective! The people at that conference knew but WE SURE DON'T! Anyway, all this might be moot (as of 9:19 the preopen bid was 2 3/8 up from the close at 2 11/32. I hope I'm just overreacting to the last year and a half of frustration at seeing a company with some good products and a pleasing pipeline continually stumble due to inept management. Ed